Literature DB >> 16343241

New agents for the treatment of ovarian cancer: the next generation.

J Dupont1, C Aghajanian, P Sabbatini, D R Spriggs.   

Abstract

Ovarian cancer shares many important characteristics with more common malignancies including breast, lung, and colon cancer. The relative chemosensitivity of ovarian cancer and other aspects of its unique biology provide opportunities for novel interventions. In this brief summary, some of the potential targets in ovarian cancer are discussed, including the HER kinases, heat shock protein, the 26S proteasome, and the angiogenesis pathway. The opportunities to change the treatment of ovarian cancer will require creative clinical trial design but the next decade promises to be filled the therapeutic advances for patients with ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16343241     DOI: 10.1111/j.1525-1438.2005.00443.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  2 in total

1.  AXL is an essential factor and therapeutic target for metastatic ovarian cancer.

Authors:  Erinn B Rankin; Katherine C Fuh; Tiffany E Taylor; Adam J Krieg; Margaret Musser; Jenny Yuan; Kevin Wei; Calvin J Kuo; Teri A Longacre; Amato J Giaccia
Journal:  Cancer Res       Date:  2010-09-21       Impact factor: 12.701

2.  Myosin II co-chaperone general cell UNC-45 overexpression is associated with ovarian cancer, rapid proliferation, and motility.

Authors:  Martina Bazzaro; Antonio Santillan; Zhenhua Lin; Taylor Tang; Michael K Lee; Robert E Bristow; Ie-Ming Shih; Richard B S Roden
Journal:  Am J Pathol       Date:  2007-09-14       Impact factor: 4.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.